IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials [Yahoo! Finance]
Clene Inc. (CLNN)
Company Research
Source: Yahoo! Finance
LOS ANGELES, CA - ( NewMediaWire ) - August 23, 2024 - Clene (NASDAQ: CLNN) , a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced positive results of two independently conducted Phase 2 clinical trials, RESCUE-ALS and HEALEY ALS Platform Trials, of CNM-Au8 for the treatment of amyotrophic lateral sclerosis ("ALS") ( https://ibn.fm/ktu4u Two Phase 2 independently conducted clinical trials showed significant improvement in key biomarkers among ALS patients who were administered CNM-Au8 Biomarker and efficacy data was submitted to the Food and Drug Administration for a granted Type C meeting request, with the company targeting an accelerated approval pathway CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, and voiced hope that ALS patients will benefit sooner rather than later Clene recently presented its latest updates and
Show less
Read more
Impact Snapshot
Event Time:
CLNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLNN alerts
High impacting Clene Inc. news events
Weekly update
A roundup of the hottest topics
CLNN
News
- Clene Inc. (NASDAQ: CLNN) had its price target lowered by analysts at Benchmark Co. from $90.00 to $84.00. They now have a "buy" rating on the stock.MarketBeat
- Clene Inc. (NASDAQ: CLNN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $86.00 to $83.00. They now have a "buy" rating on the stock.MarketBeat
- Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $31.00 price target on the stock.MarketBeat
- Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Clene Reports Third Quarter 2024 Financial Results and Recent Operating HighlightsGlobeNewswire
CLNN
Earnings
- 11/13/24 - Beat
CLNN
Sec Filings
- 11/22/24 - Form 424B3
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- CLNN's page on the SEC website